A phase 2, multicenter, randomized, double-blinded, and placebo-controlled study of the antiviral activity, safety and pharmacokinetics of VCH-759 in subjects with chronic hepatitis C-infection.
Phase of Trial: Phase I/II
Latest Information Update: 29 Sep 2009
At a glance
- Drugs Hepatitis C virus NS 5 protein inhibitors; VCH 759
- Indications Hepatitis C
- Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
- 29 Sep 2009 Company (Vertex Pharmaceuticals) added as trial sponsor and affiliate as reported by ClinicalTrials.gov.
- 01 Jul 2009 Results published in the Journal of Hepatology.
- 25 Jul 2007 Status change from recruiting to completed
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History